Abstract: Entinostat (MS-275) is a selective class I and IV histone deacetylase (HDAC) inhibitor that has shown significant promise in the treatment of breast cancer. By reversing epigenetic silencing and modulating both histone and non-histone proteins, entinostat overcomes resistance to endocrine and targeted therapies. Clinical trials, notably the ENCORE 301 study, demonstrated substantial overall survival benefits when combined with exemestane in hormone receptor-positive breast cancer, leading to its Breakthrough Therapy designation by the FDA. Furthermore, entinostat exhibits potent immunomodulatory effects, enhancing the efficacy of immunotherapies and chemotherapies in various breast cancer subtypes, including triple-negative breast cancer. This review summarizes the pharmacological activity, molecular mechanisms, structure-activity relationships, current limitations, and future perspectives of entinostat in breast cancer therapy.
1. Introduction
Breast cancer is a highly heterogeneous malignancy, and while endocrine therapies, targeted agents, and chemotherapies have improved outcomes, de novo or acquired resistance remains a significant clinical challenge [1][2]. Epigenetic modifications, such as histone hypoacetylation driven by the overexpression of histone deacetylases (HDACs), play a crucial role in silencing tumor suppressor genes and driving this therapeutic resistance [1][3][5]. Entinostat (MS-275) is an oral, synthetic benzamide derivative that selectively inhibits class I and IV HDACs [1][5]. By rewriting the epigenetic code, entinostat has emerged as a potent "episensitizing" agent capable of restoring tumor sensitivity to previously failed therapies [3][6]. Its potential to reverse resistance in hormone receptor (HR)-positive advanced breast cancer led to a Breakthrough Therapy designation by the US FDA, positioning it as a critical compound in the evolving landscape of breast cancer oncology [1][3].
2. Pharmacological Activity
Entinostat has demonstrated robust pharmacological activity across multiple breast cancer subtypes in both preclinical and clinical settings. In HR-positive advanced breast cancer, the phase II ENCORE 301 trial evaluated entinostat combined with the steroidal aromatase inhibitor (AI) exemestane in patients progressing on non-steroidal AIs. The combination significantly improved progression-free survival (PFS) and yielded an unexpected, substantial overall survival (OS) benefit of approximately 8.3 months compared to exemestane alone [1][3][5]. This promising outcome led to the initiation of the phase III E2112 registration trial to validate these findings in a larger cohort [1].
In preclinical models of HER2-overexpressing breast cancer, entinostat enhanced the efficacy of lapatinib and overcame trastuzumab/lapatinib resistance [2]. In triple-negative breast cancer (TNBC) and inflammatory breast cancer, entinostat combined with MEK inhibitors (e.g., pimasertib) or chemotherapeutic agents like doxorubicin significantly retarded tumor growth [2]. Furthermore, triple combinations, such as retinoic acid with entinostat and doxorubicin, have shown potent antitumor synergy in preclinical breast cancer models [8].
3. Molecular Mechanism of Action
The mechanisms underlying entinostat's efficacy involve both epigenetic and epigenetic-independent pathways that collectively halt tumor progression and modulate the immune microenvironment.
Epigenetic and Transcriptional Modulation: Entinostat induces histone hyperacetylation, leading to chromatin remodeling and the transcriptional activation of silenced tumor suppressor genes [1]. In letrozole-resistant models, it increases the expression of estrogen receptor (ER) and aromatase while downregulating HER2 and inhibiting AKT phosphorylation [1][2]. It also promotes FOXO3-mediated Bim1 expression and NOXA-mediated MCL1 degradation, facilitating apoptosis in resistant cells [2].
Immunomodulation: Entinostat profoundly alters the tumor microenvironment (TME). It reduces immunosuppressive cells, such as granulocytic and monocytic myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) [1][4]. Conversely, it increases the infiltration of CD8+ T cells and elevates the expression of interferons, immune checkpoint agonists (ICOSL, GITRL), and tumor-associated antigens (PSA, brachyury, CEA, MUC1) [2]. These actions reverse tumor immune escape and synergize with immune checkpoint inhibitors, IL-15 agonists, and cancer vaccines [2].
Cell Cycle and Differentiation: Entinostat sensitizes cells to doxorubicin-mediated G2 phase cell cycle arrest by inhibiting E2F and Myc genes [2]. It also targets tumor-initiating cells and modulates epithelial-mesenchymal transition (EMT), which contributes to its anti-metastatic properties [1].
4. Structure-Activity Relationship (SAR)
Entinostat (MS-275) is an oral synthetic benzamide derivative [1][5]. Unlike pan-HDAC inhibitors (such as vorinostat or panobinostat), its specific benzamide structure confers selectivity for class I (HDAC1, 2, 3) and class IV (HDAC11) enzymes, avoiding the off-target effects associated with broader HDAC inhibition [1]. This structural profile provides a long pharmacokinetic half-life, allowing for a convenient once-weekly oral dosing schedule (e.g., 5 mg weekly) on an empty stomach. This favorable pharmacokinetic profile improves patient compliance and tolerability compared to daily regimens required by other epigenetic agents [1].
5. Current Limitations
Despite its clinical promise, entinostat therapy faces several limitations. Toxicity remains a concern; the most frequent adverse events observed in the ENCORE 301 trial included fatigue (11% grade 3), neutropenia (13% grade 3), weight loss, gastrointestinal toxicity, dyspnea, and peripheral edema [1]. Additionally, the lack of validated predictive biomarkers complicates patient selection. While protein lysine hyperacetylation in peripheral blood mononuclear cells (PBMCs) has been identified as a potential prognostic biomarker for PFS, it requires further prospective validation in larger cohorts like the E2112 trial [1]. Finally, the exact mechanisms of acquired resistance to HDAC inhibitors are not fully elucidated, necessitating ongoing research into tumor-specific mutations, upregulation of efflux pumps, and TME adaptations [2].
6. Future Perspectives
The future of entinostat in breast cancer lies in rational combination strategies and biomarker-driven patient stratification. Given its ability to modulate the immune microenvironment and neutralize MDSCs, combining entinostat with immunotherapies (e.g., PD-1/PD-L1 blockade, cancer vaccines) represents a highly promising frontier, particularly for TNBC [2][4]. Furthermore, as the treatment landscape for HR-positive breast cancer evolves with the advent of CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), determining the optimal sequencing of entinostat—either in the first-line setting or post-CDK4/6 progression—will be critical [1]. Continued exploration of epigenetic signatures and non-invasive biomarkers (like PBMC acetylation status) will enable personalized therapeutic approaches, maximizing clinical benefit while minimizing unnecessary toxicity [1][8].
